Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Theranostics|October 12, 2020
SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancerXi-Yu Liu, Wang Jiang, Ding Ma, et al.
Journal for Immunotherapy of Cancer|July 20, 2021
GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancerJin-Li Wei, Si-Yu Wu, Yun-Song Yang, et al.
Food Research International (Ottawa, Ont.)|February 28, 2026
Unveiling the flavor evolution and metabolic mechanism in closed solid-state fermentation of vinegar: a multimodal omics integrationNan Zhang, Yong Jian Yu, Ke Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 7, 2022
Superenhancer drives a tumor-specific splicing variant of MARCO to promote triple-negative breast cancer progressionYun-Song Yang, Xi Jin, Qin Li, et al.
Clinical and Translational Medicine|May 6, 2022
HSP90 N-terminal inhibitors target oncoprotein MORC2 for autophagic degradation and suppress MORC2-driven breast cancer progressionFan Yang, Rui Sun, Zeng Hou, et al.
Science Translational Medicine|September 10, 2025
Interferon-induced senescent CD8+ T cells reduce anti-PD1 immunotherapy efficacy in early triple-negative breast cancerTong Fu, Xi Jin, Min He, et al.
Cell Research|February 2, 2022
Comprehensive metabolomics expands precision medicine for triple-negative breast cancerYi Xiao, Ding Ma, Yun-Song Yang, et al.
Cell Metabolism|November 12, 2020
Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic TargetsYue Gong, Peng Ji, Yun-Song Yang, et al.
Nature Communications|November 11, 2020
Characterization of the genomic landscape and actionable mutations in Chinese breast cancers by clinical sequencingGuan-Tian Lang, Yi-Zhou Jiang, Jin-Xiu Shi, et al.
The Lancet. Oncology|January 11, 2024
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trialLei Fan, Zhong-Hua Wang, Lin-Xiaoxi Ma, et al.
Pageof 3